Drug Trial Radar · NCT05855408
Effectiveness of a Second COVID-19 Vaccine Booster in Chinese Adults
Last checked: Nov 19, 2026Latest source record: May 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
10,000
Planned (sponsor's estimate)
Start
May 18, 2023
Primary completion
May 18, 2024
Study completion Dec 31, 2024
Sponsor
- Lead sponsor
- Jiangsu Province Centers for Disease Control and PreventionResearch network
- Sponsor type
- Research network
- First posted
- May 11, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a multicenter, parallel groups, partially randomized, open-label, blank-controlled adaptive platform study to evaluate the effectiveness of a second COVID-19 vaccine booster in Chinese adults who are charactered as the majority of whom with hybrid immunity of COVID-19 vaccination and COVID-19 breakthrough infection. Individuals aged 18 years and over, include the elderly over 60 years old or those with underlying diseases (history of underlying medical conditions diagnosed by a clinician, including hypertension, diabetes, heart disease, etc). The eligible participants with an interval ≥ 4 months after previous SARS-CoV-2 infection (or had never been infected) and ≥ 6 months from the first COVID-19 vaccine booster will be recruited. Participants who are not willing to receive the second booster but are consent to participate the surveillance for COVID-19, will be included as a blank control. Informed consent will be acquired from eligible participants. Other participants who are willing to receive the second booster and participate the surveillance for COVID-19, will be randomly allocated in a ratio of 1: k (k is the number of vaccine types) to the different investigational vaccines, stratified according to age and history of COVID-19 infection. The symptomatic COVID-19 cases will be reported and documented in both the investigational and control groups. The occurrence of serious adverse events within 6 months after vaccination will be observed. Moreover, blood and nasal mucosa samples will be collected on the day 0 before and day 14, month 3 and 6 after the booster vaccination in a subgroup for humoral, cellular and mucosal immunogenicity analysis. Moreover, oral specimens will be collected once for all participants on the day of enrollment.
Conditions
- COVID-19
Interventions
Intramuscularly administered Ad5-nCoV vaccineBiological
This vaccine is produced by CanSino Biologics Inc.
Aerosolized Ad5-nCoVBiological
This vaccine is produced by CanSino Biologics Inc.
DelNS1-2019-nCoV-RBD-OPT1Biological
This vaccine is produced by Wantai Biopharmaceutical Company.
SYS6006Biological
This vaccine is produced by CSPC Pharmaceutical Group Co., Ltd.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence of COVID-19 from 14 days to 6 months after the booster immunization.Time frame: from 14 days to 6 months after the booster dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Jiangsu Provincial Center for Disease Control and Prevention
Nanjing, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.